MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaci.2024.08.021

Медицинская библиотека · The Journal of allergy and clinical immunology · 2024

Hematopoietic cell transplantation for DOCK8 deficiency: Results from a prospective clinical trial.

Freeman Alexandra F, Gonzalez Corina E, Yates Bonnie, Cole Kristen, Little Lauren, Flannelly Erin, Steinberg Seth M, Mo George, Piette Nicole, Hughes Thomas E, Cuellar-Rodriguez Jennifer, Gea-Banacloche Juan, Heller Theo, Hammoud Dima A, Holland Steve M, Kong Heidi H, Young Fernanda D, Jing Huie, Kayaoglu Basak, Su Helen C, Pai Sung-Yun, Hickstein Dennis D, Shah Nirali N

Клиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

DOCK8 deficiency is a primary immunodeficiency in which allogeneic hematopoietic cell transplantation (HCT) represents the only known cure. We tested the ability of a busulfan-based regimen to achieve reliable engraftment and high levels of donor chimerism with acceptable toxicity in a prospective clinical trial in DOCK8 deficiency.

OBJECTIVES

To both evaluate the ability of HCT to reverse the clinical phenotype and to correct the immunologic abnormalities by 1 year post HCT.

METHODS

We conducted a prospective HCT trial for recipients with DOCK8 deficiency. Subjects were recruited from October 5, 2010, to December 30, 2022. Donor sources included fully matched related and unrelated donors and haploidentical donors. The reduced toxicity, myeloablative conditioning regimen contained no serotherapy. Graft-versus-host disease (GVHD) prophylaxis included either a calcineurin inhibitor with methotrexate or post-HCT cyclophosphamide (PT/Cy) followed by tacrolimus and mycophenolate mofetil. The trial was later amended to study PT/Cy in all patients. (Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 [NCT01176006].)

RESULTS

Thirty-six subjects, both children and adults (median age 16.4 years), underwent HCT for DOCK8 deficiency. Most patients, 33 of 36 (92%), achieved full (≥98%) donor chimerism in whole blood as early as day +30. With a median potential follow-up of 7.4 years, 29 (80.6%) were alive with no evidence of new DOCK8 deficiency-related complications. PT/Cy was effective in reducing the risk of acute GVHD in patients who had received matched unrelated donor and haploidentical transplants, but it was associated with transient delays in immune-reconstitution and hemorrhagic cystitis.

CONCLUSIONS

A busulfan-based HCT regimen using PT/Cy for GVHD prophylaxis and a broad range of donor types and hematopoietic cell sources were well tolerated, leading to the reversal of the clinical immunophenotype.

Для цитирования: Freeman Alexandra F, Gonzalez Corina E, Yates Bonnie, Cole Kristen, Little Lauren, Flannelly Erin, Steinberg Seth M, Mo George, Piette Nicole, Hughes Thomas E, Cuellar-Rodriguez Jennifer, Gea-Banacloche Juan, Heller Theo, Hammoud Dima A, Holland Steve M, Kong Heidi H, Young Fernanda D, Jing Huie, Kayaoglu Basak, Su Helen C, Pai Sung-Yun, Hickstein Dennis D, Shah Nirali N. Hematopoietic cell transplantation for DOCK8 deficiency: Results from a prospective clinical trial.. The Journal of allergy and clinical immunology. 2024. DOI: 10.1016/j.jaci.2024.08.021.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.